Intellia Therapeutics, Inc. Q1 FY2025 earnings call

• John Leonard highlighted progress in Q1, including dosing first patients in Phase 3 studies for HAE and ATTR, enrollment progress in HAELO and MAGNITUDE studies, RMAT designations, and building commercial foundations.
• David Lebwohl provided updates on clinical pipeline, including HAELO study enrollment progress, 2002 data updates, MAGNITUDE study enrollment for ATTR, and RMAT designations.
• Ed Dulac reviewed financials, noting cash balance, collaboration revenue changes, R&D and G&A expenses, and guidance on operating expenses decline.

No detailed breakdown of product segments with revenue contributions provided in the transcript.

• Expected year-over-year decline in GAAP operating expenses by 5%-10% in 2025.
• Cash balance sufficient to fund operating plans into first half of 2027.
• Average cash use of ~$95 million per quarter in 2025 and 2026.

• Potential impacts from regulatory environment changes at the FDA.
• Implications of pending pharmaceutical tariffs.
• Real estate transaction-related costs and their impact.

Q: About MAGNITUDE Phase 3 trial patient baseline characteristics A: David Lebwohl discussed Tafamidis use and silencer drop-out rates Q: About cash burn and OpEx A: Ed Dulac talked about average cash use and real estate transactions Q: About non-dilutive financing post-2027 A: Ed Dulac mentioned collaborations, royalty transactions, and term debt as options Q: About HAE launch dynamics A: John Leonard discussed outpatient infusion process and commercial organization Q: About enrollment in HAELO and MAGNITUDE A: John Leonard and David Lebwohl talked about enrollment progress and expectations Q: About pipeline timeline A: John Leonard focused on clinical programs and future pipeline mentions Q: About payer perception of nex-z and tafamidis A: John Leonard and David Lebwohl discussed payer insights and clinical data Q: About patient baseline in MAGNITUDE and timeline A: David Lebwohl talked about baseline characteristics and study progression Q: About 2002 value proposition and pricing A: John Leonard discussed clinical profile and pharmacoeconomic value Q: About nex-z enrollment in U.S. and impact of other drugs A: David Lebwohl talked about enrollment progress and Vutrisiran impact Q: About 2002 Phase 1 data resonance with physicians A: David Lebwohl discussed TTR reduction and efficacy data Q: About FDA changes and BLA timing A: John Leonard talked about FDA relationships and trial design Q: About MAGNITUDE 2 study enrollment and benchmarks A: John Leonard and David Lebwohl discussed enrollment rates and interim analysis Q: About MAGNITUDE trial primary endpoint and FDA view A: John Leonard talked about runway and study design